Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Electronic Cigarettes vs Combustible Cigarettes and Nicotine Gum

A Single-Center, Randomized, Open-Label, Crossover Study to Assess Elements of Abuse Liability for Three Electronic Cigarettes

The purpose of this study is to measure plasma nicotine uptake parameters, physiological measures, and subjective effect measures in smokers during and following a single ad libitum use of three electronic cigarettes versus combustible cigarettes and nicotine gum.

Study Overview

• Status: Completed
• Conditions: Smoking
• Intervention / Treatment: Other: Leading U.S. Nicotine Gum; Other: Own Brand Cigarette; Other: Electronic Cigarette #1; Other: Electronic Cigarette #2; Other: Electronic Cigarette #3

Detailed Description

This study will assess various elements that may provide information regarding the potential for electronic cigarettes (e-cigarettes) to be adopted by current smokers. These various elements include: a) nicotine pharmacokinetics (PK), b) physiological measures of pulse rate and blood pressure, and c) subjective effects measured by Urge to Smoke, Product Rating, Intent to Use Product Again, and Product Effects.

• Study Type: Interventional
• Enrollment (Actual): 45
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Nebraska
    • Lincoln, Nebraska, United States, 68502
      • Celerion

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Able to read, understand, and willing to sign an informed consent form and complete questionnaires written in English.
2. Generally healthy male or female, 21 to 60 years of age, inclusive, at Screening.
3. Expired breath carbon monoxide (ECO) level is ≥ 15 ppm and ≤ 100 ppm at the Screening and Randomization Visits, measured between 12 p.m. and 6 p.m.
4. Cigarettes are the only tobacco product used within (≤) 30 days of Screening.
5. Smokes combustible, filtered, non-menthol cigarettes, 83 mm to 100 mm in length.
6. Agrees to smoke usual brand (UB) cigarette throughout the study period. Usual brand cigarette is defined as the cigarette brand style currently smoked most frequently by the subject.
7. Smokes at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of the Investigator.
8. Response at Screening to Fagerstrom Test for Nicotine Dependence, Question 1 ("How soon after you wake up do you smoke your first cigarette?") is either "Within 5 minutes" or "6 - 30 minutes."
9. Willing to use UB cigarette, the study electronic cigarette brand styles and nicotine gum during the study period.
10. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to check-in at each Test Visit.
11. Willing to not participate for 60 days post-study in donation of blood samples or in any study that requires collection of blood samples.
12. Females of childbearing potential must be willing to use a form of contraception acceptable to the Investigator from the time of signing informed consent until study discharge.

Exclusion Criteria:

1. Clinically significant or unstable/uncontrolled acute or chronic medical conditions at Screening, as determined by the Investigator, that would preclude a subject from participating safely in the study (e.g., uncontrolled hypertension, asthma or other lung disease, cardiac disease, neurological disease or psychiatric disorders) based on safety assessments such as clinical laboratory tests, medical history, and physical/oral examinations.
2. Systolic blood pressure of > 150 mmHg or a diastolic blood pressure of > 95 mmHg at Screening, measured after being seated for at least 5 minutes.
3. Hemoglobin level is < 12 g/dL at Screening.
4. Positive test for Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen, or Hepatitis C virus.
5. Postponing a decision to quit smoking (defined as planning a quit attempt within [≤] 30 days of Screening) to participate in this study or previous attempt within (≤) 30 days prior to Screening.
6. Employed by a tobacco company, the study site, or handles unprocessed tobacco as part of their job.
7. Use of any medication or supplement that aids smoking cessation, including but not limited to any nicotine replacement therapy (e.g., nicotine gum, lozenge, patch), varenicline (Chantix), bupropion (Wellbutrin, Zyban), or lobelia extract within (≤) 30 days of Screening.
8. Females ≥ 35 years of age currently using systemic, estrogen containing contraception or hormone replacement therapy.
9. A positive urine drug screen without disclosure of corresponding prescribed concomitant medication(s), at Screening or Randomization Visit. A positive alcohol result at Screening, Randomization Visit, or at any Test Visit.
10. A female who is pregnant, lactating, or intends to become pregnant during the course of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Own Brand Cigarette	Other: Own Brand Cigarette; combustible cigarette brand style smoked most frequently by subject
Experimental: Electronic Cigarette #1; VUSE® (original flavor, 14mg nicotine)	Other: Electronic Cigarette #1; VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)
Experimental: Electronic Cigarette #2; VUSE® (original flavor, 29mg nicotine)	Other: Electronic Cigarette #2; VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
Experimental: Electronic Cigarette #3; VUSE® (original flavor, 36mg nicotine)	Other: Electronic Cigarette #3; VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)
Active Comparator: Leading U.S. Nicotine Gum	Other: Leading U.S. Nicotine Gum; 4 mg nicotine polacrilex gum

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum change in pulse rate relative to baseline	Determine the maximum change in pulse rate	Baseline and at timed intervals over 360 minutes following initiation of IP use
Change in expired carbon monoxide (ECO) relative to baseline	Assess change in ECO from baseline following IP use	Baseline and 35 minutes post-IP use
Nicotine pharmacokinetics with respect to initiation of in-clinic investigational product (IP) use following a 12-hour tobacco and nicotine abstinence	Determine area under the plasma nicotine concentration versus time curve (AUC)	-5, -0.5, 3, 5, 7.5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300, 360 minutes
Nicotine pharmacokinetics with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence	Determine maximum plasma nicotine concentration (Cmax), baseline adjusted	-5, -0.5, 3, 5, 7.5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300, 360 minutes
Nicotine pharmacokinetics with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence	Determine time to baseline-adjusted maximum plasma nicotine concentration (Tmax)	-5, -0.5, 3, 5, 7.5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300, 360 minutes
Subjective effects scores for Urge to Smoke (UTS) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence	Score subjective effects using a numeric rating scale (NRS) to determine area under the UTS score-versus-time curve [area under the effect curve (AUEC)], minimum UTS score, and time to minimum UTS score	-10, 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360 minutes
Subjective effects scores for Intent to Use Again (IUA) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence	Score subjective effects using a NRS to determine area under the IUA score-versus-time curve (AUEC) and maximum IUA score	15, 30, 45, 60, 120, 180, 240, 300, 360 minutes
Subjective effects scores for Product Ratings (PR) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence	Score subjective effects using a NRS to determine area under the PR score-versus-time curve (AUEC) and maximum PR score	15, 30, 45, 60, 120, 180, 240, 300, 360 minutes
Subjective effects scores for positive Product Effects (PE) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence	Score subjective effects using a NRS to determine area under the positive PE score-versus-time curve (AUEC) and maximum positive PE score	15, 30, 45, 60, 120, 180, 240, 300, 360 minutes
Subjective effects scores for negative Product Effects (PE) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence	Score subjective effects using a NRS to determine area under the negative PE score-versus-time curve (AUEC) and maximum negative PE score	15, 30, 45, 60, 120, 180, 240, 300, 360 minutes
Baseline cotinine measured pre-IP use	Evaluate changes in baseline cotinine to assess whether subjects substantially changed their nicotine exposure during the study	-0.5 minute only for each IP, over 5 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum change in blood pressure relative to baseline	Determine the maximum change in blood pressure	Baseline and at timed intervals over 360 minutes following initiation of IP use
Perform both CYP2A6 genotyping and phenotyping (i.e., nicotine metabolic ratio of cotinine:3-OH cotinine)	A) Determine the impact of CYP2A6 genotype and phenotype on nicotine uptake and subjective effects following a 12-hour tobacco and nicotine abstinence and B) Explore a potential relationship between CYP2A6 genotype and phenotype	Time of randomization

Collaborators and Investigators

• Sponsor: R.J. Reynolds Vapor Company
• Collaborators: Celerion; RAI Services Company
• Investigators: Principal Investigator: Michael Gartner, MD, Celerion

Publications and helpful links

General Publications

• Stiles MF, Campbell LR, Graff DW, Jones BA, Fant RV, Henningfield JE. Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability. Psychopharmacology (Berl). 2017 Sep;234(17):2643-2655. doi: 10.1007/s00213-017-4665-y. Epub 2017 Jun 20.

Study record dates

Study Major Dates

• Study Start: May 1, 2014
• Primary Completion (Actual): January 1, 2015
• Study Completion (Actual): January 1, 2015

Study Registration Dates

• First Submitted: September 26, 2014
• First Submitted That Met QC Criteria: October 16, 2014
• First Posted (Estimate): October 21, 2014

Study Record Updates

• Last Update Posted (Actual): June 4, 2018
• Last Update Submitted That Met QC Criteria: May 31, 2018
• Last Verified: May 1, 2018

More Information

Terms related to this study

• Keywords: pharmacokinetics; pharmacodynamics; e-cigarettes; adoption; electronic cigarettes; combustible cigarettes; nicotine polacrilex; own brand cigarette; subjective measures
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Cholinergic Agents; Ganglionic Stimulants; Nicotinic Agonists; Cholinergic Agonists; Nicotine
• Other Study ID Numbers: CSD1303

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No